Skip to main content

Advertisement

SpringerLink
Log in

Genotoxicity of the some selective estrogen receptor modulators: a review

  • Review
  • Published:
Cytotechnology Aims and scope Submit manuscript

Abstract

The objective of this article is to review genotoxicological profile of the major selective estrogen receptor modulators, including clomiphene, tamoxifen, toremifene, raloxifene. These drugs have been used for infertility treatment and breast cancer prevention in high risk-women. However, some studies reported that especially tamoxifen is a genotoxic agent and is related with endometrial cancer. Our review indicate that clomiphene and tamoxifen were found as genotoxic agent in majority of the tests. However published reports showed that toremifene is a weakly genotoxic agent. The genotoxic effects of raloxifene are still poorly known. Further genotoxicity studies should be conducted especially for raloxifene.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  • Al-Jassabi S, Saad A, Al-Omari A (2011) Toxic effects of tamoxifen and the protective role of silymarin and zizyphus. Middle East J Sci Res 9:110–114

    CAS  Google Scholar 

  • Althuis MD, Moghissi KS, Westhoff CL, Scoccia B, Lamb EJ, Lubin JH, Brinton LA (2005) Uterine cancer after use of clomiphene citrate to induce ovulation. Am J Epidemiol 161:607–615

    Article  Google Scholar 

  • Arriaga-Alba M, Flores-Paz R, Díaz-Hernández R, González-Patiño ME (1996) Assessment of genetic toxicity of the exposure to clomiphene citrate, with various bacterial test systems. Ginecol Obstet Mex 64:490–497

    CAS  Google Scholar 

  • Beland FA, McDaniel LP, Marques MM (1999) Comparison of the DNA adducts formed by tamoxifen in vivo. Carcinogenesis 20:471–477

    Article  CAS  Google Scholar 

  • Buckley MT, Goa KL (1989) Tamoxifen: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use. Drugs 37:451–490

    Article  CAS  Google Scholar 

  • Buzdar AU, Hortobagyi GN (1998) Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. J Clin Oncol 16:348–353

    CAS  Google Scholar 

  • Calderon-Margalit R, Friedlander Y, Yanetz R, Kleinhaus K, Perrin MC, Manor O, Harlap S, Paltiel O (2009) Cancer risk after exposure to treatments for ovulation induction. Am J Epidemiol 169:365–375

    Google Scholar 

  • Carmichael PL, Ugwumadu AH, Neven P, Hewer AJ, Poon GK, Phillips DH (1996) Lack of genotoxicity of tamoxifen in human endometrium. Cancer Res 56:1475–1479

    CAS  Google Scholar 

  • Carthew P, Lee PN, Edwards RE, Heydon RE, Nolan BM, Martin EA (2001) Cumulative exposure to tamoxifen: DNA adducts and liver cancer in rats. Arch Toxicol 75:375–380

    Article  CAS  Google Scholar 

  • Cavailles V (2002) Estrogens and receptors: an evolving concept. Climacteric 5:20–26

    Google Scholar 

  • Cavalieri EL, Devanesan P, Bosland MC, Badawi AF, Rogan EG (2002) Catechol estrogen metabolites and conjugates in different regions of the prostate of Noble rats treated with 4-hydroxyestradiol: implications for estrogen-induced initiation of prostate cancer. Carcinogenesis 23:329–333

    Article  CAS  Google Scholar 

  • Chaman A, Asmatullah (2011) Teratogenic and embryotoxic effects of clomiphene citrate in developing mice. Asian-Aust J Anim Sci 24:1053–1059

    Article  Google Scholar 

  • Cook LS, Weiss NS, Schwartz SM, White E, McKnight B, Moore DE, Daling JR (1995) Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 87:1359–1364

    Google Scholar 

  • Csemiczky G, Harlin J, Fried G (2002) Predictive power of clomiphene citrate challenge test for failure of in vitro fertilization treatment. Acta Obstet Gynecol Scand 81:954–961

    Article  Google Scholar 

  • Cuenca RE, Giachino J, Arrendondo MA, Hempling R, Edge SB (1996) Endometrial carcinoma associated with breast carcinoma: low incidence with tamoxifen use. Cancer 77:2058–2063

    Article  CAS  Google Scholar 

  • Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Jordan VC (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. J Am Med Assoc 281:2189–2197

    Article  CAS  Google Scholar 

  • Curtis RE, Boice JD, Shriner DA Jr, Hankey BF, Fraumeni JF Jr (1996) Second cancers after adjuvant tamoxifen therapy for breast cancer. J Natl Cancer Inst 88:832–834

    Article  CAS  Google Scholar 

  • Derman SG, Adashi EY (1994) Adverse effects of fertility drugs. Drug Saf 11:408–421

    Article  CAS  Google Scholar 

  • Dipple A, Pigott MA, Anderson LM (1984) 7,12-Dimethylbenzaanthracene-DNA adducts in cultured cells from mouse fetuses of different gestational ages. Cancer Lett 21:285–292

    Article  CAS  Google Scholar 

  • Duran B, Özdemir İ, Demirel Y, Özdemir Ö, Çetin A, Güven A (2006) In vivo evaluation of the genotoxic effects of clomiphene citrate on rat reticulocytes: a micronucleus genotoxicity. Gynecol Obstet Invest 61:228–231

    Article  CAS  Google Scholar 

  • Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM (1994) Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 86:527–537

    Google Scholar 

  • Gamboa da Costa GG, McDaniel-Hamilton LP, Heflich RH, Marques MM, Beland FA (2001) DNA adduct formation and mutant induction in Sprague-Dawley rats treated with tamoxifen and its derivatives. Carcinogenesis 22:1307–1315

    Article  CAS  Google Scholar 

  • Goldstein SR, Scheele WH, Rajagopalan SK, Wilkie JL, Walsh BW, Parsons AK (2000) A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Obstet Gynecol 95:95–103

    Article  CAS  Google Scholar 

  • Greaves P, Goonetilleke R, Nunn G, Topham J, Orton T (1993) Two-year carcinogenicity study of tamoxifen in Alderly Park Wistar-derived rats. Cancer Res 53:3919–3924

    CAS  Google Scholar 

  • Halbreich U, Kahn LS (2000) Selective oestrogen receptor modulators—current and future brain and behaviour applications. Expert Opin Pharmacother 1:1385–1398

    Article  CAS  Google Scholar 

  • Hastwell PW, Webster TW, Billinton MTN, Lynch AM, Harvey JS, Rees RW, Walmsley RM (2009) Analysis of 75 marketed pharmaceuticals using the GADD45a-GFP ‘GreenScreen HC’ genotoxicity assay. Mutagenesis 24:455–463

    Article  CAS  Google Scholar 

  • Hellmann-Blumberg U, Taras TL, Wurz GT, DeGregorio MW (2000) Genotoxic effects of the novel mixed antiestrogen FC-1271a in comparison to tamoxifen and toremifene. Breast Cancer Res Treat 60:63–70

    Article  CAS  Google Scholar 

  • Heres-Pulido ME, Duenas-Garcõa I, CastanÄeda-Partida L, Sanchez-Garcõa A, Contreras- Sousa M, Duran-Dõaz AA, Graf U (2004) Genotoxicity of tamoxifen citrate and 4-nitroquinoline-1-oxide in the wing spot test of Drosophila melanogaster. Mutagenesis 19:187–193

    Article  CAS  Google Scholar 

  • Holli K, Joensuu H, Valavaara R, Blanco G, Kataja V, Pukkala E (1998) The Finnish Breast Cancer Group, Tampere University Hospital. Interim results of the Finnish toremifene vs. tamoxifen adjuvant trial (abstract 332). In: Proceedings of 21st annual San Antonio Breast Cancer symposium, San Antonio (TX)

  • Jensen A, Sharif H, Kjaer SK (2009) Use of fertility drugs and risk of uterine cancer: results from a large Danish population based cohort study. Am J Epidemiol 170:1408–1414

    Article  Google Scholar 

  • Jordan VC (1993) A current view of tamoxifen for the treatment and prevention of breast cancer. Br J Pharmacol 110:507–517

    Article  CAS  Google Scholar 

  • Jordan VC (1996) Why tamoxifen? In: Jordan VC (ed) Tamoxifen: a guide for clinicians and patients. Huntington, New York, pp 15–23

    Google Scholar 

  • Lerner-Geva L, Keinan-Boker L, Blumstein T, Boyko V, Olmar L, Mashiach S, Rabinovici J, Potashnik G, Lunenfeld E, Schenker JG, Shushan A, Fishman A, Cohen I, Vagman I, Lunenfeld B (2006) Infertility, ovulation induction treatments and the incidence of breast cancer—a historical prospective cohort of Israeli women. Breast Cancer Res Treat 100:201–212

    Google Scholar 

  • Lewis JS, Craig Jordan V (2005) Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 591:247–263

    Article  CAS  Google Scholar 

  • Lippman M, Monaco ME, Bolan G (1977) Effects of estrone, estradiol, and estriol on hormone-responsive human breast cancer in long-term tissue culture. Cancer Res 37:1901–1907

    CAS  Google Scholar 

  • Liu H, Lee ES, Gajdos C, Pearce ST, Chen B, Osipo C, Loweth J, McKian K, De Los Reyes A, Wing L, Jordan VC (2003) Apoptotic action of 17beta-estradiol in raloxifene resistant MCF-7 cells in vitro and in vivo. J Natl Cancer Inst 95:1586–1597

    Article  CAS  Google Scholar 

  • London SN, Young D, Caldito G, Mailhes JB (2000) Clomiphene citrate-induced perturbations during meiotic maturation and cytogenetic abnormalities in mouse oocytes in vivo and in vitro. Fertil Steril 73:620–626

    Article  CAS  Google Scholar 

  • Magriples U, Naftolin F, Schwartz P, Carcangiu ML (1993) High grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 11:485–490

    CAS  Google Scholar 

  • Mani C, Kupfer D (1991) Cytochrome P-450-mediated activation and irreversible binding of the antiestrogen tamoxifen to proteins in rat and human liver: possible involvement of flavin-containing monooxygenases in tamoxifen activation. Cancer Res 51:6052–6058

    CAS  Google Scholar 

  • Mannerström M, Zorn-Kruppa M, Diehl H, Engelke M, Toimela T, Mäenpää Huhtala H, Uusitalo AH, Salminen L, Pappas P, Marselos M, Mäntylä M, Mäntylä E, Tähti H (2002) Evaluation of the cytotoxicity of selected systemic and intravitreally dosed drugs in the cultures of human retinal pigment epithelial cell line and of pig primary retinal pigment epithelial cells. Toxicol In Vitro 16:193–200

    Article  Google Scholar 

  • Martikainen H, Ronnberg L, Roukonen A, Kauppila A (2006) Effect of clomiphene citrate on prolactin and gonadotropin release during GnRH-analog treatment. Theriogenology 66:1560–1567

    Article  Google Scholar 

  • Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL (2005) Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin 21:1441–1452

    Article  CAS  Google Scholar 

  • Maurici D, Aardema M, Corvi R, Kleber M, Krul C, Laurent C, Loprieno N, Pasanen M, Pfuhler S, Phillips B, Sabbioni E, Sanner T, Vanparys P. Establishment of timetables for the phasing out of animal experiments for Cosmetics. http://ec.europa.eu/consumers/sectors/cosmetics/files/doc/antest/(5)_chapter_3/7_genotox-mutagen_en.pdf

  • Ohnishi T, Ohashi Y, Amano I, Nozu K (1986) An ovulation inducing agent containing clomiphene citrate causes DNA-strand breaks without SOS responses in Escherichia coli. Mutat Res 165:57–61

    CAS  Google Scholar 

  • Okuboa T, Nagaia F, Ushiyamaa K, Yokoyamab Y, Ozawac S, Kanoc K, Tomitad S, Kubod H, Kanoa I (1998) DNA cleavage and 8-hydroxydeoxyguanosine formation caused by tamoxifen derivatives in vitro. Cancer Lett 122:9–15

    Article  Google Scholar 

  • Pathak DN, Bodell WJ (1994) DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis 15:529–532

    Article  CAS  Google Scholar 

  • Philips DH, Carmichael PL, Hewer A, Cole KJ, Poon GK (1994) Alpha-hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res 54:5518–5522

    Google Scholar 

  • Phillips DH (2001) Understanding the genotoxicity of tamoxifen? Carcinogenesis 22:839–849

    Article  CAS  Google Scholar 

  • Rajaniemi H, Koskinen M, Mantyla E, Hemminki K (1998a) DNA binding of tamoxifen and its analogues: identification of the tamoxifen-DNA adducts in rat liver. Toxicol Lett 102–103:453–457

    Article  Google Scholar 

  • Rajaniemi H, Mantyla E, Hemminki K (1998b) DNA adduct formation by tamoxifen and structurally-related compounds in rat liver. Chem Biol Interact 113:145–159

    Article  CAS  Google Scholar 

  • Randal JM, Templeton A (1991) The effects of clomiphene citrate upon ovulation and endocrinology when administered to patients with unexplained infertility. Hum Reprod 6:659–664

    Google Scholar 

  • Robertson JFR (2004) Selective oestrogen receptor modulators/new antioestrogens: a clinical perspective. Cancer Treat Rev 30:695–706

    Article  CAS  Google Scholar 

  • Rodrigues DM Jr, dos Santos AR, Cavalcante AA, Alencar AP, Lopes-Costa PV, Silva BB (2012) Assessment of Micronucleus frequency in the peripheral blood of female rats in persistent estrus treated with selective estrogen receptor modulators. Environ Mol Mutagen 53:51–54

    Article  CAS  Google Scholar 

  • Roy D, Liehr JG (1999) Estrogen, DNA damage and mutations. Mutat Res 424:107–115

    Article  CAS  Google Scholar 

  • Sargent LM, Dragan YP, Bahnub N, Wiley JE, Sattler CA, Schroeder P, Sattler GL, Jordan VC, Pitot HC (1994) Tamoxifen induces hepatic aneuploidy and mitotic spindle disruption after a single in vivo administration to female Sprague-Dawley rats. Cancer Res 154:3357–3360

    Google Scholar 

  • Sargent LM, Dragan YP, Sattler C, Bahnub N, Sattler G, Martin P, Cisneros A, Mann J, Thorgeirsson S, Jordan VC, Pitot HC (1996) Induction of hepatic aneuploidy in vivo tamoxifen, toremifene and idoxifene in female Sprague-Dawley rats. Carcinogenesis 17:1051–1056

    Article  CAS  Google Scholar 

  • Seoud MAF, Johnson J, Weed JC Jr (1993) Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol 82:165–169

    CAS  Google Scholar 

  • Singh MN, Stringfellow HF, Paraskevaidis E, Hirsch PL, Martin FL (2007) Tamoxifen: important considerations of a multi-functional compound with organ-specific properties. Cancer Treat Rev 33:91–100

    Article  CAS  Google Scholar 

  • Styles JA, Davies A, Davies R, White INH, Smith LL (1997) Clastogenic and aneugenic effects of tamoxifen and some of its analogues in hepatocytes from dosed rats and in human lymphoblastoid cells transfected with human P450 cDNAs (MCL-5 cells). Carcinogenesis 18:303–313

    Article  CAS  Google Scholar 

  • Tucker MJ, Adam HK, Patterson JS (1984) Tamoxifen. In: Laurence DR, McLean AEM, Weatherall M (eds) Safety testing of new drugs. Academic Press, New York, pp 125–161

    Google Scholar 

  • Umemoto A, Lin CX, Ueyama Y, Komaki K, Santosh Laxmi YR, Shibutani S (2006) Absence of DNA adduct in the leukocytes from breast cancer patients treated with toremifene. Chem Res Toxicol 19:421–425

    Article  CAS  Google Scholar 

  • van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrère CH, Otter R, Schouten LJ, Damhuis RA, Bontenbal M, Diepenhorst FW (1994) Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 343:448–452

    Google Scholar 

  • Vijayalaxmi KK, Rai SP (1996) Studies on the genotoxicity of tamoxifen citrate in mouse bone marrow cells. Mutat Res 368:109–114

    Article  CAS  Google Scholar 

  • White INH (1999) The tamoxifen dilemma. Carcinogenesis 20:1153–1160

    Article  CAS  Google Scholar 

  • White INH, De Matteis F, Davies A, Smith LL, Crofton-Sleigh C, Venitt S, Hewer A, Phillips DH (1992) Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis 13:2197–2203

    Article  CAS  Google Scholar 

  • Williams GM, Jeffrey AM (1997) Safety assessment of tamoxifen and toremifene. Oncology 4:41–47

    Google Scholar 

  • Williams GM, Ross PM, Jeffrey AM, Karlsson S (1998) Genotoxicity studies with the antiestrogen toremifene. Drug Chem Toxicol 21:449–476

    Article  CAS  Google Scholar 

  • Wilson AS, Tingle MD, Kelly MD, Park BK (1995) Evaluation of the generation of genotoxic and cytotoxic metabolites of benzo[a]pyrene, aflatoxin B1, naphthalene and tamoxifen using human liver microsomes and human lymphocytes. Hum Exp Toxicol 14:507–515

    Article  CAS  Google Scholar 

  • Wiseman LR, Goa KL (1997) Toremifene, a review of its pharmacological properties and clinical efficacy in the management of advanced breast cancer. Drugs 54:141–160

    Article  CAS  Google Scholar 

  • Yılmaz S, Ünal F, Yılmaz E, Yüzbaşıoğlu D, Erkal İlhan S (2014) Evaluation of the genotoxicity of clomiphene citrate. Mutat Res 759:21–27

    Article  Google Scholar 

  • Zambrano MA, Targa HJ, Nazareth Rabello-Gay M (1982) Evaluation of the action of clomiphene citrate on Mouse chromosomes by the metaphase and micronucleus tests. Rev Brasil Genet 2:339–344

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Health Sciences, Ankara University, Aktaş Kavşağı, Altındağ, 06340, Ankara, Turkey

    Serkan Yilmaz & İlknur M. Gönenç

  2. Vocational School of Health Services, Gazi University, Gölbaşı, 06830, Ankara, Turkey

    Ebru Yilmaz

Authors
  1. Serkan Yilmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. İlknur M. Gönenç
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ebru Yilmaz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Serkan Yilmaz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yilmaz, S., Gönenç, İ.M. & Yilmaz, E. Genotoxicity of the some selective estrogen receptor modulators: a review. Cytotechnology 66, 533–541 (2014). https://doi.org/10.1007/s10616-014-9710-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10616-014-9710-7

Keywords

Search

Navigation